Courtney DiNardo
科特尼·迪纳尔多
MD, MSCE
Professor, Department of Leukemia白血病科教授
👥Biography 个人简介
Preeminent investigator in IDH-mutant AML who led the clinical development of enasidenib and ivosidenib. Her work translated IDH mutation biology into FDA-approved targeted therapies, establishing a new paradigm of precision oncology in leukemia.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IDH2 Inhibition with Enasidenib
Led the pivotal Phase I/II trial of enasidenib in IDH2-mutant AML, demonstrating durable responses and differentiation syndrome, directly enabling FDA approval in 2017.
IDH1 Inhibition and Combination Strategies
Defined clinical activity of ivosidenib alone and in combination with azacitidine in IDH1-mutant AML and MDS, resulting in regulatory approvals and new treatment standards.
Representative Works 代表性著作
Enasidenib in mutant IDH2 relapsed or refractory AML
Blood (2017)
First-in-human Phase I/II study showing enasidenib achieves 40% overall response rate in IDH2-mutant AML, enabling the first IDH2-targeted therapy approval.
Ivosidenib combined with azacitidine in newly diagnosed IDH1-mutant AML
New England Journal of Medicine (2021)
Phase III trial demonstrating significant event-free survival improvement, leading to FDA approval of this combination for frontline IDH1-mutant AML.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Naval Daver
The University of Texas MD Anderson Cancer Center
Gail Roboz
Weill Cornell Medicine / NewYork-Presbyterian Hospital
关注 科特尼·迪纳尔多 的研究动态
Follow Courtney DiNardo's research updates
留下邮箱，当我们发布与 Courtney DiNardo（The University of Texas MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment